#United States #Cranford #Cancer Treatment #LYMPHIR #Citius Oncology

Citius Oncology's 2025 Performance Report

Citius Oncology, Inc. (Nasdaq: CTOR), a prominent player in oncology treatments, released its financial results for the fiscal year ending September 30, 2025. This year marks a turning point for the company, especially with the commercial launch of LYMPHIR™, an innovative immunotherapy targeting adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL).

A Historic Revenue-Generating Year

Leonard Mazur, CEO of Citius Oncology, characterized 2025 as pivotal, noting the shift from a pre-revenue stage to a robust revenue-generating entity. The company commenced the U.S. rollout of LYMPHIR in December 2025, a development that promises not only to deliver vital treatment options to patients but also to enhance the financial landscape of Citius Oncology.

To strengthen its financial position and support LYMPHIR's commercialization, Citius completed strategic financings totaling $36 million, including an $18 million private placement and registered direct offering executed on December 10, 2025. These funds are crucial for driving product adoption and ensuring long-term sustainability in the market.

Collaborations and International Expansion

Significant partnerships have been established to bolster LYMPHIR's distribution. Citius Oncology entered into agreements with three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR across a network of healthcare organizations, including major medical centers, specialized hospitals, community oncology practices, and infusion centers. Moreover, the company's access to LYMPHIR in 19 international markets through regional distribution partners underscores its commitment to global outreach via Named Patient Programs (NPPs).

Leveraging Advanced Technology

In a strategic move, Citius has partnered with Verix to implement the Tovana AI-powered platform. This collaboration aims to improve commercial targeting and enhance provider engagement, vital for the successful rollout of LYMPHIR in the U.S. market. With these advanced analytics, Citius Oncology seeks to refine its market strategies and maximize operational efficiency, ensuring that healthcare professionals and patients can access LYMPHIR effectively.

Financial Overview of 2025

As of September 30, 2025, Citius Oncology reported cash and cash equivalents of $3.9 million. The company has been active in securing funding through various means, including an $18 million registered direct offering completed in December 2025, which is expected to enhance its financial health moving forward.

Despite these advancements, the fiscal year concluded with a net loss of $24.8 million or ($0.34) per share, in comparison to the previous year's loss of $21.1 million. Notably, research and development expenses surged to $6.4 million, indicating ongoing investment in product development and commercialization efforts.

The Path Ahead

Management at Citius Oncology remains optimistic about LYMPHIR's potential, estimating the initial market could exceed $400 million, an indication of the growing demand for effective treatment options in oncology. The first-in-class immunotherapy is poised to fill an underserved niche, reflecting Citius Oncology's innovative approach to tackling cancer treatment challenges.

As the company continues to develop its pipeline and establish competitive positioning through robust intellectual property protections, the future looks promising. Citius Oncology's focus will be on optimizing its commercial strategies and expanding its reach into additional markets, ensuring sustained value creation for both patients and shareholders.

In summary, 2025 has proven to be a landmark year for Citius Oncology. With a promising product like LYMPHIR making waves in the oncology space, the company is well on its path to redefining its operational footprint and achieving substantial growth in the coming years.